BackEnzymatica AB (publ) Overview

Enzymatica AB (publ) EBIT

Track Enzymatica AB (publ)'s EBIT ($-42M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$3.79M
↑ 53.51% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

-$41.74M
↑ 21.72% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Enzymatica AB (publ) (ENZY.ST) FAQ

The latest EBIT for ENZY.ST is $-42M as of September 2026. That compares with $-53M in the prior-year period — up 21.7% year over year. That is below the sector sector average of $2.4T. Investors often review this figure alongside Enzymatica AB (publ)'s historical trend and sector peers before judging valuation or financial health.

Over the past year, ENZY.ST's EBIT moved from $-53M to $-42M — a 21.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Enzymatica AB (publ)'s operating scale or balance-sheet position.

Against its sector companies, ENZY.ST currently prints $-42M for EBIT, while the sector average sits near $2.4T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Enzymatica AB (publ)'s growth, margins, and balance sheet.

A EBIT figure of $-42M for ENZY.ST is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.4T. Explore the charts below for those layers of context.

After noting ENZY.ST's EBIT ($-42M), review year-over-year change from $-53M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.